Ascend Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Ascend Therapeutics aims to develop two non-hormone drugs delivered via hydroalcoholic gels that penetrate quickly into the skin.
You may also be interested in...
Don't Try This At Home: Zazzle-Created EstroGel Promo Card Fizzles With FDA
Low-grade sales piece touting cost savings with Ascend Therapeutics’ product lacks risk information; it is just the seventh Rx citation by FDA this year.
Rediscovering Existing Drugs
There's been a lot of talk lately about unlocking the hidden value from existing products, that is, drugs that have gone all the way from pure discovery, through the FDA regulatory process and into the hands of patients. These are the industry's greatest assets; they've already distinguished themselves from millions of other compounds by passing the myriad tests related to disease relevancy, safety, efficacy, and more safety, since safety isn't ultimately known until drugs disseminate through the treatment population, years after approval. Recently, there's been a shift to applying the industrial revolution in de novo drug discovery--the tools for screening and assaying libraries of random compounds-to existing drugs, as companies look for new products by reprofiling, repurposing, and redirecting the development of old drugs.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.